Gilead Sciences, Inc. (GILD) — closed signal from December 19, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on March 19, 2026.
Predicted vs. what happened
What happened
Reached its target in 39 days.
The thesis — published December 19, 2025
Gilead is a steady buy-for-holding over the next few months rather than a fast mover. Recent Phase 3 results for a new HIV drug matched a top competitor, and a new senior legal hire may help the company run smoother. Expect gains to come gradually as investors slowly revalue the stock; wider market shifts away from defensive healthcare could limit upside.
Primary drivers
- New Phase 3 HIV results increase confidence in future drug options
- Senior legal hire reduces uncertainty about company execution
- Steady earnings make the stock attractive in volatile markets
- Weaker buy signals mean gains may be slower and stay in a range
How it played out
GILD: target reached in 39 days
Lyra published GILD at $123.8 on 2025-12-19 with a short-term view and expected growth of 12%. The thesis pointed to new Phase 3 HIV results, a senior legal hire, steady earnings in volatile markets, and weaker buy signals that could make gains slower and range-bound.
Inside the window, the stock reached the $138.66 target in 39 days. It later peaked at $157.29 on 2026-02-11, with a peak gain of 27.1%. By 2026-03-19 it ended at $141.11, still above the target. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.